title: Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8alphabeta versus CD8alphaalpha expression.
abstract: In our previous studies, CTL that were sensitive to low concentrations of peptide Ag were found to be far superior to those requiring high concentrations of Ag for reducing viral burden when adoptively transferred into SCID mice. Thus it is important that we understand the mechanisms that control the requirement for peptide Ag with the long-term goal of selectively expanding these exquisitely sensitive cells in vivo. Although TCR affinity is one parameter that can affect the CTL sensitivity for Ag, we investigated whether additional mechanisms may also be involved. In studies using a TCR transgenic mouse model, we successfully generated CTL with identical TCR affinity that possess distinctly different activation requirements. Using both peptide Ag and anti-CD3 Ab to activate the CTL lines of high vs low avidity, we found that the variations in activation threshold are the result of differences in the required number of engaged TCR. Additionally, we have observed that the ratio of CD8alphabeta to CD8alphaalpha is significantly greater in CTL lines that are more sensitive to TCR engagement, which may contribute to the lower activation threshold of these CTL following CD3 engagement. These studies identify a novel mechanism by which the activation requirements of Ag-specific CTL are determined by demonstrating a direct correlation between the sensitivity to TCR engagement, the expression of levels CD8alphabeta vs alphaalpha, and the amount of peptide Ag required to reach the threshold for activation.
authors.affiliation: Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
authors.forename: A G
authors.initials: AG
authors.lastname: Cawthon
authors.forename: H
authors.initials: H
authors.lastname: Lu
authors.forename: M A
authors.initials: MA
authors.lastname: Alexander-Miller
mesh_terms: D000818:Animals; D000941:Antigens / Q000008:administration & dosage; D017252:CD3 Complex / Q000378:metabolism*; D016827:CD8 Antigens / Q000378:metabolism*; D002460:Cell Line; D003432:Cross-Linking Reagents; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D010455:Peptides / Q000008:administration & dosage / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D000941:Antigens; D017252:CD3 Complex; D016827:CD8 Antigens; C409469:CD8 antigen, alpha chain; D003432:Cross-Linking Reagents; D004268:DNA-Binding Proteins; D010455:Peptides; C499308:Rag2 protein, mouse; D011948:Receptors, Antigen, T-Cell; C064655:V(D)J recombination activating protein 2